Education
About Us
Working with TipRanks
Follow Us
Fennec Pharmaceuticals (FENC)
NASDAQ:FENC
FENC Stock Chart & Stats
$7.66
-$0.02(-0.33%)
At close: 4:00 PM EST
$7.66
-$0.02(-0.33%)
Day’s Range― - ―
52-Week Range$4.68 - $9.92
Previous Close$6.08
Volume58.66K
Average Volume (3M)81.47K
Market Cap
$257.10M
Enterprise Value$311.49M
Total Cash (Recent Filing)$21.93M
Total Debt (Recent Filing)$18.09M
Price to Earnings (P/E)―
Beta1.37
Next Earnings
Apr 01, 2026EPS Estimate
0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding34,139,973
10 Day Avg. Volume67,165
30 Day Avg. Volume81,470
Financial Highlights & Ratios
PEG Ratio3.19
Price to Book (P/B)-22.88
Price to Sales (P/S)2.83
P/FCF Ratio4.98
Enterprise Value/Market Cap1.21
Enterprise Value/Revenue8.03
Enterprise Value/Gross Profit8.62
Enterprise Value/Ebitda-83.98
Forecast
1Y Price Target
$13.00Price Target Upside69.71% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Guideline EndorsementsPEDMARK is recommended for the adolescent and young adult (AYA) population by the National Comprehensive Cancer Network (NCCN) with a 2A endorsement.
International ExpansionEuropean and international advancement continuing with the acceptance of PEDMARQSI® by the Scottish Medicines Consortium (SMC) for use in Scotland.
Product AdoptionA large national oncology group has added PEDMARK to its formulary for patients under 40 years of age, signaling momentum for broader adoption in community settings.
Bears Say
Fennec Pharmaceuticals News
FENC FAQ
What was Fennec Pharmaceuticals’s price range in the past 12 months?
Fennec Pharmaceuticals lowest stock price was $4.68 and its highest was $9.92 in the past 12 months.
What is Fennec Pharmaceuticals’s market cap?
Fennec Pharmaceuticals’s market cap is $257.10M.
When is Fennec Pharmaceuticals’s upcoming earnings report date?
Fennec Pharmaceuticals’s upcoming earnings report date is Apr 01, 2026 which is in 101 days.
How were Fennec Pharmaceuticals’s earnings last quarter?
Fennec Pharmaceuticals released its earnings results on Nov 13, 2025. The company reported -$0.02 earnings per share for the quarter, beating the consensus estimate of -$0.022 by $0.002.
Is Fennec Pharmaceuticals overvalued?
According to Wall Street analysts Fennec Pharmaceuticals’s price is currently Undervalued.
Does Fennec Pharmaceuticals pay dividends?
Fennec Pharmaceuticals does not currently pay dividends.
What is Fennec Pharmaceuticals’s EPS estimate?
Fennec Pharmaceuticals’s EPS estimate is 0.04.
How many shares outstanding does Fennec Pharmaceuticals have?
Fennec Pharmaceuticals has 34,139,973 shares outstanding.
What happened to Fennec Pharmaceuticals’s price movement after its last earnings report?
Fennec Pharmaceuticals reported an EPS of -$0.02 in its last earnings report, beating expectations of -$0.022. Following the earnings report the stock price went up 2.211%.
Which hedge fund is a major shareholder of Fennec Pharmaceuticals?
Currently, no hedge funds are holding shares in FENC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Fennec Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$13.00 (69.71% Upside)
$13.00 (69.71% Upside)
Insider Transactions
Sold Shares
Worth $2.8M over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
77.20%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-28.95%
Trailing 12-Months
Company Description
Fennec Pharmaceuticals
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
FENC Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted strong revenue growth and market adoption for PEDMARK, supported by strategic expansions and new accounts. However, increased operating expenses and dependency on market expansion present challenges. The momentum in PEDMARK's adoption and international expansion efforts suggest positive future prospects.View all FENC earnings summariesFENC Stock 12 Month Forecast
Average Price Target
$13.00
▲(69.71% Upside)
Technical Analysis
Satellos Bioscience
―
Arch Biopartners
―
NervGen Pharma
―
Bright Minds Biosciences
―
Eupraxia Pharmaceuticals
―
Ownership Overview
12.55% Insiders
4.17% Mutual Funds
― Other Institutional Investors
77.73% Public Companies and
Individual Investors